Keywords: Pro Bono Bio, PolyTherics, TheraPEG technology, Blood factor proteins, Hemophilia

Pro Bono Bio obtains exclusive licence from PolyTherics to TheraPEG technology

Article | 10 September 2012

Print This

Anglo-Russian health care group Pro Bono Bio (PBB) and PolyTherics, a privately owned UK company and a provider of solutions ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in